
There is a more recent version of this eprint available. Click here to view it.
Angyal, A., Longet, S., Moore, S. et al. (48 more authors) (Submitted: 2021) T-Cell and antibody responses to first BNT162b2 vaccine dose in previously SARS-CoV-2-infected and infection-naive UK healthcare workers: a multicentre, prospective, observational cohort study. [Preprint - SSRN Electronic Journal] (Submitted)
Abstract
Background: Following a single dose of BNT162b2 mRNA vaccine, higher antibody titres are observed following prior SARS-CoV-2 infection than in infection-naive individuals, but T-cell responses are less well defined.<br><br>Methods: We sampled healthcare workers (HCWs) enrolled in the UK PITCH study, before and after BNT162b2 mRNA vaccination. We measured spike-specific antibody, and quantified T-cell responses by IFNγ ELISpot assay and intracellular staining of peripheral blood mononuclear cells (PBMC), comparing SARS-CoV-2-naïve individuals to those with prior infection.<br><br>Findings: HCWs aged 22 to 71 years received one (n=216) or two (n=21) vaccine doses. After a single dose, the spike-specific T-cell response was six-fold higher in previously-infected vs. naive individuals (median 340 vs. 58 SFU/10<sup>6</sup> PBMC, p<0.0001; fresh PBMC, n=99). The T-cell response in previously-infected individuals after one vaccine dose was equivalent to naïve individuals receiving two vaccine doses (median 158 vs. 165 SFU/10<sup>6</sup> PBMCs, p=0.65; cryopreserved PBMC, n=117). Anti-spike IgG levels following a single dose in those previously infected (median 512.9 antibody units/ml (AU/ml)) were 6.8-fold higher vs. naïve individuals following one dose (median 75.0 AU/ml, p<0.0001) and 2.9-fold higher than naïve individuals given two doses three weeks apart (179.9 AU/ml, p=0.03). Following vaccination, plasma from individuals with prior infection demonstrated higher <i>in vitro</i> neutralisation of the B.1.351 variant of concern compared to naive individuals.<br><br>Interpretation: Following a single BNT162b2 dose, HCWs with a prior history of SARS-CoV-2 infection have significantly higher T-cell and antibody responses than naive individuals.Funding UK Department of Health and Social Care and UK Coronavirus Immunology Consortium.<br><br>Funding: UK Department of Health and Social Care and UK Coronavirus Immunology Consortium.<br><br>Conflict of Interest: D.W.E. declares lecture fees from Gilead, outside the submitted work. The other authors have no conflicts of interest to declare.<br><br>Ethical Approval: PITCH was recognised as a sub-study of SIREN on 2 December 2020, which was approved by the Berkshire Research Ethics Committee, Health Research 250 Authority (IRAS ID 284460, REC reference 20/SC/0230).
Metadata
Item Type: | Preprint |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2021 The Author(s). |
Keywords: | PITCH Consortium |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > Department of Infection, Immunity and Cardiovascular Disease |
Funding Information: | Funder Grant number DEPARTMENT OF HEALTH AND SOCIAL CARE 1603HB006/PP4 |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 11 May 2023 14:32 |
Last Modified: | 11 May 2023 14:32 |
Published Version: | http://dx.doi.org/10.2139/ssrn.3812375 |
Status: | Submitted |
Publisher: | Elsevier BV |
Identification Number: | 10.2139/ssrn.3812375 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:198943 |
Available Versions of this Item
- T-Cell and antibody responses to first BNT162b2 vaccine dose in previously SARS-CoV-2-infected and infection-naive UK healthcare workers: a multicentre, prospective, observational cohort study. (deposited 11 May 2023 14:32) [Currently Displayed]